Novartis, CH0012005267

Novartis signs USD 7.8 billion deal: Goldman raises target for Novartis stock to CHF 113.00

Published on 10/06/2026 at 13:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abogen gets USD 575 million upfront and USD 7.2 billion milestones. Novartis stock costs EUR 125.80 on October 6, 2026 versus EUR 125.29, plus 0.41 percent.

Forscherin in weißem Kittel pipettiert in Reagenzglas im sterilen Pharmalabor — Novartis AG CH0012005267 – Forscherin pipettiert präzise in steriler Pharmalaborumgebung mit Reagenzgläsern, Illustration mit AI erstellt.

Novartis signs a potential USD 7.80 billion mRNA licensing deal with Abogen, while Goldman Sachs raised its target for Novartis stock to CHF 113.00 on October 1, 2026. The deal announced on October 2 gives Novartis exclusive rights to experimental therapy ABO2203 and options on additional RNA medicines, according to Reuters.

RNA deal carries milestone risk

Novartis will pay USD 575.00 million upfront, while Abogen can receive up to USD 7.20 billion in additional milestone payments if ABO2203 advances through development and gains regulatory approval. The arrangement therefore puts less cash at risk initially than the headline value suggests, but its eventual scale depends on clinical, regulatory and commercial execution.

ABO2203 is designed to target B cells involved in autoimmune diseases including lupus and rheumatoid arthritis. Reuters reported that Novartis described Abogen's RNA technology as complementary to its existing autoimmune strategy, while the company continues to advance other pipeline programs.

Goldman keeps a cautious view

Markets Insider reported on October 1, 2026 that Goldman Sachs maintained its Sell rating and raised the target from CHF 110.00 to CHF 113.00. The target remains below the CHF 119.96 closing value cited in that report, showing that the analyst view had not yet embraced the deal's full pipeline potential.

The latest reported quarter also supplies a useful operating baseline. For the quarter ended June 30, 2026, Novartis reported revenue of CHF 14.16 billion and net profit of CHF 3.21 billion, compared with CHF 14.84 billion and CHF 4.04 billion respectively a year earlier, according to Markets Insider. The figures frame the Abogen agreement as a pipeline investment rather than an immediate earnings driver.

Next results arrive October 27

Novartis has scheduled its financial results for the third quarter of 2026 on October 27, 2026, according to its Novartis investor calendar. That report will give investors a nearer-term test of revenue momentum while the new mRNA assets remain at an early development stage.

Novartis stock stays above prior close

Novartis stock was trading at EUR 125.80 at Lang & Schwarz on October 6, 2026 at 1:04 p.m. CEST, up 0.41 percent versus the EUR 125.29 prior close at Lang & Schwarz from October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.